CEO & President
Terrance Lall
Terry has served as President & CEO of Hybridyne Health from inception, and has been the leader behind development of the ProxiScan imaging system. Mr. Lall also negotiated Hybridyne's Corporate R&D Agreement with the USA Department of Energy (National Laboratories Brookhaven National Laboratory), and serves as the principal interface of Hybridyne and all external organizations. Mr. Lall has also assisted in the financing and structuring of other biotechnology companies that led to successful NASDAQ listings. His earlier career spans a variety of ventures in a diverse set of industries, including being a key member of the leadership team at Leach & Garner/Sovereign Inc., refining hundreds of millions of dollars of gold from foreign sources; and working directly with Presidents of several third world countries in South America to revise their gold laws and policies.
CLINICAL ADVISORS
Dr. Neil Fleshner; MD, MPH, FRCSC
Neil Fleshner is Head of the Division of Urology at global leading oncology research centre Princess Margaret Hospital (PMH) and Professor at the University of Toronto. Aside from surgical practice, Dr. Fleshner conducts research on urologic cancer prevention with an emphasis on prostate cancer. Dr. Fleshner is certified in both urology and epidemiology. He earned his MPH degree from the School of Public Health at Columbia Universit,y and completed his oncology training at Memorial Sloan Kettering Cancer Center. His current projects include 2 randomized trials of nutritional intervention in prostate cancer as well as laboratory work assessing oxidative biomarkers and cell cycle regulation in prostate cancer cells exposed to micronutrients. He has authored over 100 scientific papers.
Dr. Jack Barkin; MD, FICS, FACS, DABU, MHM, CCPE, FRCS
Dr Barkin received his Fellowship from the Royal college of Physicians and Surgeons in Canada in 1982. He has been the Chief of Surgery, Chief of Urology and Chief of Staff at Humber River hospital in Toronto, and is a clinical professor with the University of Toronto. A prolific clinical investigator, writer, publisher and speaker, he has spoken over 1500 times all over the world to urologist and family doctors on areas concerning urology. He has always been interested in new medical technologies to improve patient health, and has brought both High Intesity Focussed Ultrasound (HIFU) and Urolift to Canada, as well as being a leading practitioner of Robotic Surgery. He is also Executive Editor-in-Chief of the Canadian Journal of Urology.
Dr Toni Finelli, MD, MSc, FRCSC
Dr. Finelli completed his urology residency in 2003 at the University of Toronto and became a Fellow of the Royal College of Physicians and Surgeons. During his residency, he earned a Masters of Science degree through the Surgical Scientist Program. Before joining the Faculty in 2005, he completed a fellowship in Laparoscopic Urologic Oncology at the Cleveland Clinic Foundation. His clinical practice focuses on the management of urologic malignancies with minimally invasive techniques. Specifically, he performs laparoscopic radical prostatectomy, nephrectomy, partial nephrectomy and adrenalectomy. His research interest is the assessment of new surgical technology.
COMMERCIAL ADVISORS
Paul Godfrey; CM
Mr. Godfrey served as President and CEO of the National Post, President and CEO of the Toronto Blue Jays Baseball Club, and spent 16 years with Sun Media Corporation, eventually taking the role of President and CEO. Mr. Godfrey has a proud record of public service including a record four terms (11 years) as the Chairman of the Municipality of Metropolitan Toronto. He is the Chairman of the Board of RioCan Real Estate Investment Trust. He also serves on the board of Cargojet Income Fund and is Vice Chair of Baycrest Centre for Geriatric Care. Mr. Godfrey has a Bachelor of Applied Science in Chemical Engineering from the University of Toronto
SCIENTIFIC ADVISORS
Dr Ralph James, PhD
Dr. James is currently a tenured Senior Scientist and Group Leader, and has served as the Associate Laboratory Director for the Energy, Environment and National Security with DOE’s Brookhaven National Laboratory (BNL) in the USA. At BNL he conducts basic and applied research devoted to semiconductor materials, radiation detectors, and gamma-ray imaging systems. The output of Dr. James’ research is finding numerous applications in the fields of gamma-ray spectrometers, nuclear medicine, solar energy, astrophysics, and security. He is a Fellow of the IEEE, SPIE, AAAS, OSA, MRS and APS, and he has received numerous prestigious international honors for his work on detectors and imaging, including Discover Magazine Innovator of the Year, 6 R&D-100 awards, IEEE Outstanding Radiation Instrumentation Award, 50 World’s Best Technologies Award, Battelle Innovation Award, and Frost & Sullivan Invention of the Year among others.
Dr Yonggang Cui, PhD
Dr. Cui is a Scientist at BNL and has extensive experience on detectors for radiation-detection applications and the development of advanced readout electronics. Dr. Cui is involved in developing field-portable nuclear detectors for spectroscopy and imaging, focusing on designing the radiation detectors, optimizing the interface between the detector and readout electronics, packaging, and field tests. He has authored and co-authored over 150 scientific technical papers related to the design of readout electronics design and the development of detectors. He is a two-time winner of R&D Magazine's R&D 100 Award for detector development and imaging applications, and also received Battelle Innovation Award, Frost & Sullivan Invention of the Year, Long Island’s “Man of the Year” in Science among others.
Dr Youngho Seo, PhD
Dr Seo is an Associate Professor and Director of Nuclear Imaging Physics in the Department of Radiology and Biomedical Imaging, Associate Professor in Residence in the Department of Radiation Oncology at the University of California, San Francisco, and Physicist Faculty Scientist at Lawrence Berkeley National Laboratory. Dr Seo leads a group of physicists and engineers working in the field of radionuclide and x-ray imaging instrumentation and physics, and directs the UCSF PRL. His primary research focus is to use quantitative SPECT/CT, PET/CT, and PET/MR molecular imaging for a broad range of research areas from small animal imaging using dedicated animal imaging systems and basic instrumentation development to physics analysis of clinical research data.